CAD System for Lung Cancer

If lung cancer is found and treated while localized, a patient's five-year survival can increase to 49% at stage I, according to the American Cancer Society.

The CAD system detects suspicious pulmonary nodules on chest x-rays. Whereas it does not identify the disease independently, this system "reads” the x-ray images, processes the information, and displays the data for the radiologist to detect an abnormality.

The system, called RapidScreen, was developed by Riverain Medical
(Miamisburg, OH, USA; www.riverainmedical.com), and received the U.S. Food and Drug Administration (FDA) premarket approval in July 2001. The technology is based on an algorithm to detect and classify 87 exclusive signatures that are associated with solitary pulmonary nodules. In clinical studies, radiologists using RapidScreen improved the identification of tumors between 9-14 mm by 23%.





Related Links:
Riverain Medical